Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib plus pemetrexed versus osimertinib alone in EGFR T790M-positive advanced lung adenocarcinoma after first-line resistance
ChiCTR1800019710Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Non-small cell lung cancer adenocarcinoma (NSCLC) comparing Osimertinib + pemetrexed with Osimertinib monotherapy (2 arms). Primary endpoint: Progression-free survival. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
osimertinibpemetrexed
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800019710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019710.